首页> 外文期刊>Yangtze Medicine >The Effect of Neoadjuvant Chemotherapy on ER, PR and HER-2 Expression in Breast Cancer
【24h】

The Effect of Neoadjuvant Chemotherapy on ER, PR and HER-2 Expression in Breast Cancer

机译:新辅助化疗对乳腺癌ER,PR和HER-2表达的影响

获取原文
           

摘要

Objective : Through comparativing the change of the ER, PR and HER-2 expression in tumor tissue before and after neoadjuvant chemotherapy (NAC) in locally advanced breast cancer patient, to discuss whether there is influence for NACon ER, PR, HER-2 expression for breast cancer. Also, the relationship of ER, PR, HER-2 and chemosensitivity is also discussed. Methods: The expressions of ER, PR and HER2 in paraffin sections of breast cancer tissues from 51 patients before and after NAC were detected by immunohistochemical method. The assessment for the relationships between ER, PR, HER-2 and the efficiently of NAC is done. Results: For the 51 peoples, there is no statistical significance for change of ER, PR and HER-2 expression before and after NAC (P > 0.05). There is statistical significance for the differences of chemotherapeutic effectiverate between ER negative and ER positive, PR negative and PR positive, HER2 over-expressed group and HER2 non over-expressed group (P < 0.05). Pathological complete response (pCR) was related to molecular classification and the number of chemotherapy cycles. There is statistically significant or prognisis difference about hormone receptor, HER2 over-expressed and three-negative breast cancer (P < 0.05). Conclusion: NAC maybe could not change the expression of ER and PR, and HER2 for breast cancer patients. The patients with HER-2 over-expressed are not sensitive to chemotherapy, and the patients with ER or PR negative get more benefits from chemotherapy. The breast cancer patients who could obtain pCR could get better prognosis after NAC.
机译:目的:通过比较局部晚期乳腺癌患者新辅助化疗(NAC)前后肿瘤组织中ER,PR和HER-2表达的变化,探讨是否对NACon ER,PR,HER-2表达有影响乳腺癌。此外,还讨论了ER,PR,HER-2与化学敏感性之间的关系。方法:采用免疫组织化学方法检测51例NAC患者乳腺癌组织中石蜡切片中ER,PR和HER2的表达。评估ER,PR,HER-2与NAC的效率之间的关系。结果:在51个人中,NAC前后ER,PR和HER-2表达的变化均无统计学意义(P> 0.05)。 ER阴性和ER阳性,PR阴性和PR阳性,HER2过表达组和HER2非过表达组的化疗有效率差异有统计学意义(P <0.05)。病理完全缓解(pCR)与分子分类和化疗周期数有关。激素受体,HER2高表达和三阴性乳腺癌在统计学上或认知上有差异(P <0.05)。结论:NAC可能不能改变乳腺癌患者的ER,PR和HER2的表达。 HER-2过表达的患者对化疗不敏感,ER或PR阴性的患者从化疗中获益更多。能够获得pCR的乳腺癌患者在NAC后可以得到更好的预后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号